That's one way to look at it. But I see something different.
I see a CEO who has navigated a difficult path. Over the past 7 years there have been countless hit pieces and short attacks, numerous baseless allegations and frivolous lawsuits, a pandemic, a recession and several competitors' drugs biting the dust to get the company to where it is today: front and center at CTAD 2022 presenting data about a novel MOA for treating Alzheimer's disease.
That's one way to look at it. But I see something different. He's done a creative job of promoting an old, previously tried, marginally-/in-effective MOA and now the jig is up. This will be clearer IF results are poor.